• 1.

    Block GA, et al.. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15:22082218.

  • 2.

    Gutierrez OM, et al.. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359:584592.

  • 3.

    Navaneethan SD, et al.. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis 2009; 54:619637.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Koiwa F, et al.. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial 2005; 9:336339.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Sprague SM, et al.. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003; 63:14831490.

  • 6.

    Block GA, et al.. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350:15161525.

  • 7.

    Palmer SC, et al.. Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. PLoS Med 2013; 10:e1001436.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Block GA, et al.. Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial. J Am Med Assoc 2017; 317:156164.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Isakova T, et al.. KDOQI US commentary on the 2017 KDIGO clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Am J Kidney Dis 2017; 70:737751.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Cunningham J, et al.. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68:17931800.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Chertow GM, et al.. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367:24822494.

  • 12.

    Parfrey PS, et al.. The effects of cinacalcet in older and younger patients on hemodialysis: the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Clin J Am Soc Nephrol 2015; 10:791799.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13.

    Friedl C, et al.. Mortality in dialysis patients with cinacalcet use: large observational registry study. Eur J Intern Med 2017; 42:8995.

  • 14.

    Alem AM, et al.. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 2000; 58:396399.

  • 15.

    Behets GJ, et al.. Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism. Kidney Int 2015; 87:846856.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16.

    Moe SM, et al.. Effects of cinacalcet on fracture events in patients receiving hemodialysis: the EVOLVE Trial. J Am Soc Nephrol 2015; 26:14661475.

Calcimimetics in End Stage Renal Disease

  • 1 Susan Ziolkowski, MD, is Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellow, and Graham Abra, MD, is a clinical assistant professor at Stanford University. Abra is also director, Medical Clinical Affairs, at Satellite Healthcare.
Restricted access
Save